HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM)

CUSIP: 40434H104

Q2 2016 13F Holders as of 30 Jun 2016

Type / Class
Equity / COM
Total 13F shares
3,401,108
Share change
-100,802
Total reported value
$9,065,520
Price per share
$2.71
Number of holders
22
Value change
-$279,403
Number of buys
6
Number of sells
6

Quarterly Holders Quick Answers

What is CUSIP 40434H104?
CUSIP 40434H104 identifies HTGM - HTG MOLECULAR DIAGNOSTICS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) as of Q2 2016

As of 30 Jun 2016, HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) was held by 22 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 3,401,108 shares. The largest 10 holders included Novo A/S, FMR LLC, PUTNAM INVESTMENTS LLC, BlackRock Advisors LLC, Cormorant Asset Management, LLC, BlackRock Group LTD, VANGUARD GROUP INC, MACKENZIE FINANCIAL CORP, BlackRock Investment Management, LLC, and RENAISSANCE TECHNOLOGIES LLC. This page lists 22 institutional shareholders reporting positions in this security for the Q2 2016 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.